13 Drugs Added to Knowledgebase

We recently added 13 new drugs to the knowledgebase:

• DTX401 a gene therapy for the treatment of glycogen storage disease type Ia (GSDIa) is being developed by Ultragenyx Pharmaceutical 
• DTX301 a gene therapy for the treatment of ornithine transcarbamylase (OTC) deficiency is being developed by Ultragenyx Pharmaceutical 
• Donidalorsen an Antisense oligonucleotide for the treatment of hereditary angioedema is being developed by Ionis Pharmaceuticals,
• VX-548 a selective NaV1.8 inhibitor for the treatment of pain following bunionectomy, or abdominoplasty is being developed by Vertex
• Foslevodopa and foscarbidopa a dopamine precursor for the treatment of advanced parkinson's disease is being developed by AbbVie
• Eladocagene exuparvovec a gene therapy for the treatment of severe aromatic L-amino acid decarboxylase (AADC) deficiency is being developed by PTC Therapeutics 
• AZD8233 an Antisense PCSK9 inhibitor for the treatment of hypercholesterolemia is being developed by Ionis Pharmaceuticals and AstraZeneca
• Ampreloxetine a norepinephrine reuptake inhibitor for the treatment of neurogenic orthostatic hypotension is being developed by Theravance Biopharma
• Lifileucel a tumor infiltrating lymphocyte for the treatment of metastatic melanoma is being developed by Iovance Biotherapeutics
• Ziresovir an RSV fusion (F) protein inhibitor for the treatment of respiratory syncytial virus (RSV) is being developed by Ark Biopharmaceutical
• JDQ443 a KRAS G12C inhibitor for the treatment of non-small cell lung cancer harboring the KRAS G12C mutation is being developed by Novartis
• Enoblituzumab an Anti-B7-H3 monoclonal antibody for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer (NSCLC) and urothelial cancer is being developed by MacroGenics
• Cilofexor a farnesoid X receptor agonist for the treatment of non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis is reduce “Off Time” in Parkinson’s disease is being developed by Cerevance

The Prescribe Right Pharmaceutical Pipeline Tracker is the most comprehensive source of clinical information for late-stage investigational drugs. The knowledgebase allows you to track 1,034 pipeline and recently approved drugs supported by 2,611 announced and published study results.